Emyria’s data-backed cannabinoid treatments are changing lives
Emyria Limited (ASX: EMD) is an Australian drug development company that focuses on novel treatments for patients with
News
ASX: EMD
- About
- News and media
- Upcoming Events
- Recent Events
- Investment Webcasts
- Trading Webcasts
- The Insider
- Meet the CEOs
- Meet the Fund Manager
- Merewether Capital
- OC Funds Management
- Horizon 3 Biotech
- Ellerston Capital
- Thorney Investment Group
- TAMIM Asset Management
- Technical Investing
- Armytage Private Limited
- Eley Griffiths Group
- Pengana Capital Group
- Eiger Capital
- Capital H Management
- NAOS Asset Management
- K2 Asset Management
- Viriathus Australia
- Cyan Investment Management
- Gleneagle Securities
- Yarra Capital Management
- OC Funds Management
- Arnott Capital
- ASX Company Webcasts
- Prescient Therapeutics (ASX: PTX)
- TZ Limited (ASX: TZL)
- Volpara Health Technologies (ASX: VHT)
- NSX Limited (ASX: NSX)
- Praemium Limited (ASX: PPS)
- Wellnex Life (ASX: WNX)
- Uniti Group (ASX: UWL)
- Pacific Smiles Group (ASX: PSQ)
- LawFinance Limited (ASX: LAW)
- Janison Education (ASX: JAN)
- Netccentric Limited (ASX: NCL)
- Registry Direct (ASX: RD1)
- INVESTMENTS
- OPEN INVESTMENTS
- RECENT INVESTMENTS
- Kalinda Wholesale Investment
- Gateway – Series 34
- Dispersion Series 9
- Diversified Commodities Index Series 5
- Mrs Clucks Wholesale Investment
- Wellnex Life Shortfall Placement
- Wattle Health Rights issue
- Registry Direct Shortfall Placement
- Yumble Kids
- TZ Limited Rights Issue
- TZ Limited Placement
- VHM Limited
- BlackRock Multi Asset Strategy
- Connec
- Techgen Initial Public Offering
- Far East Gold
- Red Piranha
- REACH WHOLESALE
- Trading
- Reach Corporate
- CONTACT